Regular readers will be aware that here at the SoPD, we are on a mission to change the way we clinically test drugs (Click here for the most recent rant on this topic).
We have a lot of interesting drugs waiting in the pipeline to be clinically tested and an eager (read: desperate) population of individuals affected by Parkinson’s, but we are missing one critical part of the equation: better tools of assessment.
How can we determine whether a drug is actually working or not? And how can we better monitor people over time on said drug?
Our current methods assessing individuals with Parkinson’s rely heavily on clinical rating scales and brain imaging. These are basic tools at best, conducted episodically (annually in general, or once every 2-6 months during a clinical trial), and provide little in the way of useful objective data (on an individual basis).
In today’s post, we will look at a single aspect of Parkinson’s – sleep – and try to nut-out a better/more informative method of assessing it over time.
The Bluesky project. Source: Mirror
Last week tech industry giants Pfizer and IBM made an big announcement.
It was news that I have been quietly waiting to hear for some time.
It related to their “BlueSky Project” – a collaboration between the two companies to provide better methods of assessment/monitoring of Parkinson’s.
The two companies announced that they are now ready to start accepting the first participants for a new clinical trial.
And it is a really intriguing study for one simple reason:
The entire trial will take place inside one house.
They say that “we are what we eat”, and food can certainly have a major impact on health and wellbeing.
Recently, a research report has been published that looks into the topic of food in the context of Parkinson’s disease.
And the results are interesting.
In today’s post we will outline the new research, discuss the results, and what they mean for people living with Parkinson’s disease.
Seattle. Source: Wikipedia
Established in 1978, Bastyr University is an alternative medicines institute.
The original campus (Bastyr now has a second campus in San Diego, California) is tucked into the idyllic forested area of Saint Edward State Park on the edge of Lake Washington, just north-east of downtown Seattle (Washington).
Hang on a moment – ‘alternative medicines’?
While I can understand that some readers may immediately question why ‘alternative medicines’ are being mentioned on the “Science” of Parkinson’s disease website, here at the SoPD HQ we entertain any and all ideas with regards to Parkinson’s disease. And we are certainly open to any data that may be of interest to the Parkinson’s community.
Particularly, when that data comes from this individual:
This is Dr Laurie Mischley. She’s awesome.
She is an Associate Clinical Investigator at Bastyr University, a guru when it comes to nutrition, and our first port of call when we field questions regarding Parkinson’s disease and diet. You can see her in action in this video (recommended viewing for those with Parkinson’s disease and interested in the topic of diet/nutrition):
Importantly, Dr Mischley is also responsible for most of the clinical study data that we have on Acetylcysteine (also known as N-acetylcysteine or simply NAC) in Parkinson’s disease (Click here to read more about this).
And she is currently co-ordinating the “Complementary & Alternative Medicine Care in Parkinson’s Disease” (CAM Care in PD) study, which is attempting to ‘collect as much data as possible over a five-year period with the hope of finding dietary and lifestyle factors associated with a slower disease progression’. The study is still recruiting and I would encourage readers to take time to enrol in the study and fill in the survey (Click here to learn more).
This ongoing CAM study (and Dr Mischley’s efforts) has recently borne fruit that will be of real interest to the Parkinson’s community. It is a research report that reviews dietary and nutritional supplemental factors that can impact Parkinson’s disease progression.
This is the study here: